Schizophrenia: Moving beyond monoamine antagonists

Molecular Interventions

Volumn 8, Issue 2, 2008, Pages 99-107

  Conn, P Jeffrey ^a   Tamminga, Carol ^b   Schoepp, Darryle D ^c   Lindsley, Craig ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALX 5047; AMPHETAMINE; CHLORPROMAZINE; GLYCINE TRANSPORTER; METABOTROPIC RECEPTOR; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR AGONIST; MUSCARINIC M3 RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PLACEBO; SARCOSINE; SEROTONIN 2A AGONIST; UNCLASSIFIED DRUG; XANOMELINE;

ALLOSTERISM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG BINDING SITE; DRUG EFFECT; DRUG STRUCTURE; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; REVIEW; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; COGNITION; HUMANS; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA;

EID: 42249095496     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.8.2.7     Document Type: Review

References (55)

1. Hyman, S.E. and Fenton, W.S. What are the tight targets for psychopharmacology? Science 299, 350-351 (2003).
2. Green, M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153, 321-330 (1996).
3. Nuechterlein, K.H., Barch, D.M., Gold, J.M., Goldberg, T.E., Green, M.F., and Heaton, R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 72, 29-39 (2004).
4. Geyer, M.A. and Tamminga, C. MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia. Psychopharmacology 174, 1-162 (2004).
5. Buchanan, R.W., Davis, M., Goff, D. et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31, 5-19 (2005).
6. Olincy, A., Harris, J.G., Johnson, L.L. et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry. 63, 630-638 (2006).
7. Bymaster, F.P., Felder, C., Ahmed, S., and McKinzie, D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 1, 163-181 (2002).
8. Lahti, A.C., Weiler, M.A., Tamara Michaelidis, B.A., Parwani, A., and Tamminga, C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25, 455-467 (2001).
9. Patil, S.T., Zhang, L., Martenyi, F. et al. Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat. Med. 13, 1264 (2007).
10. Boidick, N.C., Offen, W.W., Levey, A.I. et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54, 465-473 (1997).
11. Boidick, N.C., Offen, W.W., Shannon, H.E., Satterwhite, J., Lucas, R., Van Lier, R., and Paul, S.M. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 11, S16-22 (1997).
12. Kaufer, D. Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9, S8-S14 (1998).
13. Feldman, H. Treating Alzheimer's disease with cholinesterase inhibitors: What have we learned so far? Int. Psychogeriatr. 14, S3-S5 (2002).
14. Rosler, M. The efficacy of cholinesterase inhibitors in treating the behavioral symptoms of dementia. Int. J. Clin. Pract. Suppl. 127, 20-36 (2002).
15. Assal, F. and Cummings, J.L. Neuropsychiatric symptoms in the dementias. Curr. Opin. Neurol. 15, 445-450 (2002).
16. Grossberg, G.T. The ABC of Alzheimer's disease: Behavioral symptoms and their treatment. Int. Psychogeriatr. 14, S27-S49 (2002).
17. Bullock, R. and Cameron, A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series. Curr. Med. Res. Opin. 18, 258-264 (2002).
18. Mirza ,N.R., Peters, D., and Sparks, R.G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 9, 159-186 (2003).
19. Shekhar, A., Potter, W.Z., Lienemann, J., Sunblad, K., Lightfoot, J., Herrera, J., Unverzagt, F., Bymaster, F.P., and Felder, C.C. ACNP abstracts (2001).
20. Neubauer, H., Sundland, D., and Gershon, S. Ditran and its antagonists in a mixed psychiatric population. J. Nerv. Ment. Dis. 142, 265-277 (1966).
21. Shirey, J.K., Xiang, Z., Orton, D. et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nature Chem. Biol. 4, 42-50 (2008).
22. Schoepp, D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299, 12-20 (2001).
23. Schoepp, D.D., Monn, J.A., Marek, G.J., Aghajanian, G., and Moghaddam B. LY354740: A systemically active mGlu2/3 receptor agonist. CNS Drug Rev. 5, 1-12 (1999).
24. Linden, A.M. and Schoepp, D.D. Metabotropic glutamate receptors targets for neuropsychiatric disorders. Drug Discov. Today 3, 507-517 (2006).
25. Schoepp, D.D., Jane, D.E., and Monn, J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38, 1431-1476 (1999).
26. Monn, J.A. and Schoepp, D.D. (2000) Metabotropic glutamate receptor modulators: Recent advances and therapeutic potential. Ann. Rep. Med. Chem. 35, 1-10.
27. Battaglia, G., Monn, J.A., and Schoepp, D.D. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740. Neuropsysiol. Clin. Neurosci. 229, 161-164 (1997).
28. Weinberger, D. Schizophrenia drug says goodbye to dopamine. Nature Med. 13, 1018-1019 (2007).
29. Lahti, A.C., Holcomb H.H., Gao X.-M., and Tamminga C.A. NMDA-sensitive glutamate antagonism: A human model of psychosis. Neuropsychopharmacology 21, S158-S169 (1999).
30. Krystal, J.H., Belger, A., D'Souza, C., Anand, A., Charney, D.S., Aghajanian, G.K., and Moghaddam, B. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 22, S143-S157 (1999).
31. Anis, N.A., Berry, S.C., Burton,N.R., and Lodge, D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 79, 565-575 (1983).
32. Aghajanian, G.K. and Marek, G.J. Serotonin-glutamate interactions: A new target for antipsychotic drugs. Neuropsychopharmacology 21, S122-S133 (1999).
33. Schoepp, D.D. and Marek, G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: Novel agents for schizophrenia? Curr. Drug Targets CNS Neurol. Disord. 1, 215-225 (2002).
34. Patil, S.T., Zhang, L., Martenyi, F., Lowe, S., Jackson, K., Monn, J.A., Johnson, B.G., and Schoepp, D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: Results from a phase 2 clinical trial. Nature Med. 13, 1102-1107 (2007).
35. Moghaddam, B. and Adams, B.W. Reversal of phencyclidine effects by group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352 (1998).
36. Cartmell J., Monn, J.A., and Schoepp, D.D. The mGlu2/3 agonists, LY354740 and LY379268, selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 291, 161-170 (1999).
37. Rorick-Kehn, L.M., Johnson, B.G., Knitowski, K.M. et al. Pharmacological properties of a structurally-novel, potent, selective mGlu2/3 receptor agonist: In vivo characterization of LY404039 in animal models of psychiatric disorders. Psychopharmacology 193, 212-136 (2007).
38. Fell, M.J., Svensson, K.A., Johnson, B.G., and Schoepp, D.D. Evidence for the role of mGlu2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. J. Pharmacol. Exp. Ther. (2008).
39. Gonzalez-Maeso J., Ang R.L., Yuen T. et al. Identification of a serotonin/ glutamate receptor complex implicated in psychosis. Nature 452, 93-97 (2008).
40. Swanson, C.J. and Schoepp, D.D. A role for noradrenergic neuronal transmission in the actions of phencyclidine and the antipsychotic and anti-stress effects of mGlu2/3 receptor agonists. Ann. N.Y. Acad. Sci. 1003, 309-317 (2003).
41. Marek, G.J., Wright, R.A., Schoepp, D.D., Monn, J.A., and Aghajanian, G.K. Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292, 76-87 (2000).
42. Rorick-Kehn, L.M., Johnson, B.G., Burkey, J.L. et al. Pharmacological and pharmacokinetic properties of a structurally novel, potent, selective mGlu2/3 receptor agonist: In vitro characterization of LY404039. J. Pharmacol. Exp. Ther. 321, 308-317 (2007).
43. Olney, J.W. and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52, 998-1007 (1995).
44. Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., and Javitt, D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 55, 165-171 (2004).
45. Olney, J.W., Newcomer, J.W., and Farber, N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatry Res. 33, 523-533 (1999).
46. Williams, D.L. and Jr., Lindsley, C.W. Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). Curr. Topics Med. Chem. 5, 825-846 (2005).
47. Smith, K.E., Borden, L.A., Hartig, P.R., Branchek, T., and Weinshank, R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8, 927-935 (1992).
48. Morrow, J.A., Collie, I.T., Dunbar, D.R., Walker, G.B., Shahid, M., and Hill, D.R. Molecular cloning and functional expression of the human glycine transporter GlyT2 and chromosomal localization of the gene in the human genome. FEBS Lett. 439, 334-340 (1998).
49. Zafra, F., Gomeza, J., Olivares, L., Aragón, C., and Giménez, C. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur. J. Neurosci. 7, 1342-1352 (1995).
50. Atkinson, B.N., Bell, S.C., and De Vivo, M. ALX 5407: A potent, selective inhibitor of the hGlyT1 glycine transporter. Mol. Pharm. 60, 1414-1420 (2001).
51. Sur, C. and Kinney, G.G. The therapeutic potential of glycine transporter-1 inhibitors. Expert. Opin. Investig. Drugs 13, 515-521 (2004).
52. Ceccarelli, S.M., Pinard, E., Stadler, H., and Alberati, D. Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperidines as GlyT1 antagonists with improved pharmacological profile. Bioorg. Med. Chem. Lett. 16, 354-357 (2005).
53. Williams, J.B., Mallorga, P.J., Lemaire, W. et al. Development of a scintillation proximity assay for analysis of Na+/Cl- -dependent neurotransmitter transporter activity. Anal. Biochem. 321, 31-37 (2003).
54. Lindsley, C.W., Zhao, Z., Leister, W.H. et al. Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides. ChemMedChem 1, 807-811 (2006).
55. Zeng, Z., O'Brien, J.A., Lemaire, W., O'Malley, S.S. et al. A novel radioligand for glycine transporter 1: Characterization and use in autoradiographic and in vivo brain occupancy studies. Nuc. Med. Biol. 35, 315-325 (2008).